logo

Fibrogen Inc. (FGEN)



Trade FGEN now with
  Date
  Headline
4/12/2021 7:23:35 AM FibroGen Says FDA Granted Fast Track Designation For Anti-CTGF Antibody, Pamrevlumab
12/22/2020 7:08:27 AM FibroGen Doses First Patient In ZEPHYRUS-2 Phase 3 Trial Of Pamrevlumab In Patients With Idiopathic Pulmonary Fibrosis
11/27/2020 2:08:10 AM Astellas, FibroGen: Japan's MHLW Approved EVRENZO For Treatment Of Anemia Of CKD In Adult Patients Not On Dialysis
8/11/2020 7:18:24 AM FibroGen Says First Patient Enrolled In Pamrevlumab Phase 3 Clinical Trial
6/23/2020 7:13:39 AM FibroGen Begins Phase 2 Study Investigating The Efficacy And Safety Of Pamrevlumab In Patients With Acute COVID-19
6/8/2020 7:28:45 AM FibroGen Says First Patient Enrolled In Pamrevlumab Clinical Trial In Patients With Severe COVID-19
5/20/2020 10:56:29 PM European Medicines Agency Accepts Astellas' Marketing Authorization Application For Roxadustat
4/20/2020 7:15:56 AM FibroGen Says Disappointed With UK Court's Decision
3/2/2020 4:05:53 PM FibroGen Q4 Loss/share $1.12 Vs. Profit $0.23 Year Ago
2/11/2020 5:18:36 PM FibroGen Announces FDA Acceptance Of NDA For Roxadustat For Treatment Of Anemia Of Chronic Kidney Disease
1/30/2020 12:10:03 AM Astellas Submits SNDA For Approval Of Evrenzo For Anemia Associated With CKD In Non-Dialysis Dependent Patients In Japan